NCT06600152

Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients With Clean Surgical Wounds.

A Randomized, Open-label, Investigational Safety Evaluation of the Microporous Annealed Particle (MAP) Wound Matrix (TT101) Device as a Volumetric Biomaterial Scaffold Applied to Clean Wounds After Skin Cancer Surgery With Mohs Micrographic Surgery (MMS) Compared to Control.

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Tempo Therapeutics · Industry
• Sex: All
• Age: 22 Years
• Healthy volunteers: Not accepted

Summary

A randomized, open-label, investigational safety evaluation of the Microporous Annealed Particle (MAP) Wound Matrix (TT101) device as a volumetric biomaterial scaffold applied to clean wounds after skin cancer surgery with Mohs micrographic surgery (MMS) compared to control.

Conditions

• Wound Heal

Interventions

Type	Name	Description
DEVICE	MAP Wound Matrix	The MAP Wound Matrix is indicated for the management of full thickness wounds, including surgical sites, donor skin graft sites, wound dehiscence, lacerations, and draining wounds. The application of MAP Wound Matrix will occur immediately after Mohs surgery once hemostasis has been achieved
DEVICE	DuoDerm	DuoDerm is a hydrocolloid dressing will be topically applied to the wound immediately following Mohs surgery according to the manufacturer\'s instructions.

Timeline

• Start date: 2024-08-26
• Primary completion: 2026-08-30
• Completion: 2026-08-30
• First posted: 2024-09-19
• Last updated: 2025-08-11

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated device study